In the cardiac arrhythmia subgroup, the increased adjusted HRs should be interpreted cautiously because GLP-1 RA use was not associated with the risk of other heart disease, coronary artery disease, and heart failure. The gene discussed is GLP1R; the disease is cardiac arrhythmia.